eligibility_summary
Adults 18–75 with relapsed/refractory multiple myeloma 60–180 days post‑ASCT (first or repeat auto‑SCT), ≥2 prior lines incl PI/IMiD/anti‑CD38, in ≥PR, KPS>70, adequate counts/organ function, not pregnant, contraception required. Exclude: ocular disease or contact lenses, ≥G2 neuropathy, recent therapy/mAbs or surgery, unstable liver/renal disease, active infection, CV disease, uncontrolled HIV, HBV/HCV+, other cancers, prior allo‑SCT, amyloidosis/POEMS/PCL, cognitive/psychiatric issues.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Belantamab mafodotin (Blenrep), an antibody-drug conjugate (ADC) comprising a humanized anti-BCMA (TNFRSF17) IgG1 monoclonal antibody linked to the microtubule toxin MMAF, IV every 8 weeks as maintenance after salvage autologous HCT in relapsed/refractory multiple myeloma. Mechanism: Binds BCMA on malignant plasma cells, is internalized, delivers MMAF to disrupt microtubules and induce apoptosis, Fc domain can engage immune effector functions (ADCC/ADCP). Cells/pathways targeted: BCMA-expressing plasma/myeloma cells, microtubule cytoskeleton in tumor cells, Fcγ receptor–bearing effector cells (e.g., NK cells, macrophages). Key outcomes: safety/tolerability, CR rate, PFS/OS, MRD, immune reconstitution. Phase 1, single-arm, status: terminated (<75% participation).